BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 25259908)

  • 1. Clinical and molecular features of Hürthle cell carcinoma of the thyroid.
    Chindris AM; Casler JD; Bernet VJ; Rivera M; Thomas C; Kachergus JM; Necela BM; Hay ID; Westphal SA; Grant CS; Thompson GB; Schlinkert RT; Thompson EA; Smallridge RC
    J Clin Endocrinol Metab; 2015 Jan; 100(1):55-62. PubMed ID: 25259908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TERT promoter mutations in thyroid cancer: a report from a Middle Eastern population.
    Qasem E; Murugan AK; Al-Hindi H; Xing M; Almohanna M; Alswailem M; Alzahrani AS
    Endocr Relat Cancer; 2015 Dec; 22(6):901-8. PubMed ID: 26354077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients.
    Loh KC; Greenspan FS; Gee L; Miller TR; Yeo PP
    J Clin Endocrinol Metab; 1997 Nov; 82(11):3553-62. PubMed ID: 9360506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TERTp mutation is associated with a shorter progression free survival in patients with aggressive histology subtypes of follicular-cell derived thyroid carcinoma.
    Penna GC; Pestana A; Cameselle JM; Momesso D; de Andrade FA; Vidal APA; Araujo Junior ML; Melo M; Fernandes PV; Corbo R; Vaisman M; Sobrinho-Simões M; Soares P; Vaisman F
    Endocrine; 2018 Sep; 61(3):489-498. PubMed ID: 29948935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic factors in patients with Hürthle cell neoplasms of the thyroid.
    Lopez-Penabad L; Chiu AC; Hoff AO; Schultz P; Gaztambide S; Ordoñez NG; Sherman SI
    Cancer; 2003 Mar; 97(5):1186-94. PubMed ID: 12599224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Refining Dynamic Risk Stratification and Prognostic Groups for Differentiated Thyroid Cancer With TERT Promoter Mutations.
    Kim TH; Ki CS; Kim HS; Kim K; Choe JH; Kim JH; Kim JS; Oh YL; Hahn SY; Shin JH; Jang HW; Kim SW; Chung JH
    J Clin Endocrinol Metab; 2017 May; 102(5):1757-1764. PubMed ID: 28323925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic effects of TERT promoter mutations are enhanced by coexistence with BRAF or RAS mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients.
    Song YS; Lim JA; Choi H; Won JK; Moon JH; Cho SW; Lee KE; Park YJ; Yi KH; Park DJ; Seo JS
    Cancer; 2016 May; 122(9):1370-9. PubMed ID: 26969876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Follicular thyroid carcinoma: histology and prognosis.
    D'Avanzo A; Treseler P; Ituarte PH; Wong M; Streja L; Greenspan FS; Siperstein AE; Duh QY; Clark OH
    Cancer; 2004 Mar; 100(6):1123-9. PubMed ID: 15022277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Therapy concept in differentiated thyroid gland carcinoma--results of 25 years with 257 patients].
    Gemsenjäger E; Heitz PU; Martina B; Schweizer I
    Praxis (Bern 1994); 2000 Nov; 89(44):1779-97. PubMed ID: 11109916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in the clinicopathological characteristics and genetic alterations of follicular thyroid cancer.
    Song YS; Lim JA; Min HS; Kim MJ; Choi HS; Cho SW; Moon JH; Yi KH; Park DJ; Cho BY; Park YJ
    Eur J Endocrinol; 2017 Dec; 177(6):465-473. PubMed ID: 28864536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TERT promoter mutation as an early genetic event activating telomerase in follicular thyroid adenoma (FTA) and atypical FTA.
    Wang N; Liu T; Sofiadis A; Juhlin CC; Zedenius J; Höög A; Larsson C; Xu D
    Cancer; 2014 Oct; 120(19):2965-79. PubMed ID: 24898513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma.
    Tsang RW; Brierley JD; Simpson WJ; Panzarella T; Gospodarowicz MK; Sutcliffe SB
    Cancer; 1998 Jan; 82(2):375-88. PubMed ID: 9445196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas.
    Liu T; Wang N; Cao J; Sofiadis A; Dinets A; Zedenius J; Larsson C; Xu D
    Oncogene; 2014 Oct; 33(42):4978-84. PubMed ID: 24141777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Operative strategy for follicular thyroid cancer in risk groups stratified by pTNM staging.
    Lin JD; Chao TC; Chen ST; Huang YY; Liou MJ; Hsueh C
    Surg Oncol; 2007 Aug; 16(2):107-13. PubMed ID: 17600699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas.
    Melo M; da Rocha AG; Vinagre J; Batista R; Peixoto J; Tavares C; Celestino R; Almeida A; Salgado C; Eloy C; Castro P; Prazeres H; Lima J; Amaro T; Lobo C; Martins MJ; Moura M; Cavaco B; Leite V; Cameselle-Teijeiro JM; Carrilho F; Carvalheiro M; Máximo V; Sobrinho-Simões M; Soares P
    J Clin Endocrinol Metab; 2014 May; 99(5):E754-65. PubMed ID: 24476079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prospective therapy study in differentiated thyroid carcinoma].
    Gemsenjäger E; Heitz P; Martina B
    Schweiz Med Wochenschr; 1995 Nov; 125(46):2226-36. PubMed ID: 8525342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TERT Promoter Mutation Spatial Heterogeneity in a Metastatic Follicular Thyroid Carcinoma: Implications for Clinical Work-Up.
    Stenman A; Hysek M; Jatta K; Bränström R; Darai-Ramqvist E; Paulsson JO; Wang N; Larsson C; Zedenius J; Juhlin CC
    Endocr Pathol; 2019 Sep; 30(3):246-248. PubMed ID: 31154561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma.
    Rivera M; Ghossein RA; Schoder H; Gomez D; Larson SM; Tuttle RM
    Cancer; 2008 Jul; 113(1):48-56. PubMed ID: 18484584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management and outcome of recurrent well-differentiated thyroid carcinoma.
    Palme CE; Waseem Z; Raza SN; Eski S; Walfish P; Freeman JL
    Arch Otolaryngol Head Neck Surg; 2004 Jul; 130(7):819-24. PubMed ID: 15262757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Follicular thyroid carcinoma in an iodine-replete endemic goiter region: a prospectively collected, retrospectively analyzed clinical trial.
    Asari R; Koperek O; Scheuba C; Riss P; Kaserer K; Hoffmann M; Niederle B
    Ann Surg; 2009 Jun; 249(6):1023-31. PubMed ID: 19474675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.